What is Vor?
Vor Bio operates within the biotechnology sector, specifically targeting autoimmune diseases. Its core focus is the development and potential commercialization of telitacicept, a proprietary fusion protein designed to combat autoantibody-driven conditions. The company's strategy involves advancing this therapeutic candidate through rigorous clinical trials, including Phase 3 development, with the ultimate goal of bringing a new treatment option to patients globally. This enterprise-level backing positions Vor Bio to navigate the complex path from clinical development to market.
How much funding has Vor raised?
Vor has raised a total of $382.6M across 4 funding rounds:
Series A
$42M
Series B
$110M
Private Equity
$55.6M
Stock/Share Issuance
$175M
Series A (2019): $42M with participation from RA Capital Advisors, RA Capital Management, and 5AM Ventures
Series B (2020): $110M led by Fidelity Management & Research Company, Pagliuca Family Office, RA Capital Management, and Alexandria Venture Investments
Private Equity (2024): $55.6M supported by Reid Hoffman and RA Capital Management
Stock/Share Issuance (2025): $175M, investors not publicly disclosed
Key Investors in Vor
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. RA Capital aims to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Fidelity Management & Research Company
Fidelity Investments is an international provider of financial services and investment resources that help individuals and institutions meet their financial objectives.
What's next for Vor?
With a significant enterprise-level funding injection and a recent strategic investment, Vor Bio is poised for accelerated growth and development. The company's immediate future likely involves the continued progression of telitacicept through its Phase 3 trials, a crucial step towards regulatory approval and market entry. This substantial capital infusion will also support operational scaling, potential expansion of research and development efforts, and the establishment of commercialization infrastructure. The strategic nature of the recent financing suggests strong confidence from investors in Vor Bio's therapeutic approach and its potential to capture a significant share of the autoimmune disease market.
See full Vor company page
